Nucelion Therapeutics, an arm of Bharat Biotech, and Pandorum Technologies plan to collaborate on two ophthalmology projects backed through the PRIP programme. The work targets investigational therapies for advanced keratopathy and for wet age-related macular degeneration (wet AMD).
Both outlets describe the partnership in similar terms, focusing on the therapeutic areas rather than providing details on timelines or trial design. The Hindu emphasises that Nucelion is Bharat Biotech’s arm and specifically frames the effort as involving two PRIP-backed projects, while Business Line presents the same two-project scope without adding that additional corporate context. No other distinct elements are included in the provided summaries, including no confirmed outcomes or schedules.